Akcea Therapeutics
74 articles with Akcea Therapeutics
-
Companies from across the globe provide updates to their pipelines and businesses, with news from BioNTech, Mologic, Akcea, RedHill, and more.
-
Diamond Pharma Services Supports Akcea Therapeutics in Gaining EU Regulatory Approval for WAYLIVRA Treatment for Familial Chylomicronaemia Syndrome (FCS)
3/25/2019
Diamond Pharma Services has provided EU regulatory support to Akcea since 2016, resulting in a positive CHMP opinion for the grant of a Conditional Marketing Authorisation for WAYLIVRA
-
Biotech and pharma companies from across the globe share data and news in a weekly roundup.
-
PTC to Expand Product Portfolio in Latin America with WAYLIVRA™
3/4/2019
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its partner, Akcea Therapeutics, affiliate of Ionis Pharmaceuticals, received a positive opinion for WAYLIVRA™ by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA
-
Akcea and Ionis Receive Positive EU CHMP Opinion for WAYLIVRATM (volanesorsen)
3/1/2019
Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending conditional marketing authorization for WAYLIVRA
-
Akcea® Recognizes Rare Disease Day Through Efforts to Increase Awareness of Hereditary Transthyretin Amyloidosis and Familial Chylomicronemia Syndrome
2/28/2019
Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat patients with serious and rare diseases, today announced the company’s support for Rare Disease Day 2019 for patients living with hereditary transthyretin (hATTR) amyloidosis and familial chylomicronemia syndrome (FCS) and their caregivers, including bringing several of them together to participate in a live panel discussion related to their disease.
-
AKCEA-APO(a)-LRx Advances as Leading Pharmaceutical Company Exercises Option to License
2/25/2019
Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced that Novartis has exercised its option to license AKCEA-APO(a)-LRx, a drug to treat patients with elevated levels of lipoprotein(a), or Lp(a), and established cardiovascular disease (CVD). AKCEA-APO(a)-LRx, referred to by Novartis as TQJ230, was discovered by Ionis and co-developed by Akcea and Ionis.
-
Phase 2 Results on AKCEA-APO(a)-LRx Presented in Late-Breaking Clinical Trial Presentation at AHA Scientific Sessions
11/12/2018
Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced that data from the Phase 2 clinical study of AKCEA-APO(a)-LRx in patients with established cardiovascular disease (CVD) and elevated levels of lipoprotein(a), or Lp(a), were presented in a late-breaking clinical trial presentation at the American Heart Association Scientific Sessions in Chicago November 10, 2018.
-
Akcea and Ionis Announce Late-Breaking Presentation of Data From AKCEA-APO(a)-LRx at the American Heart Association Scientific Sessions
11/8/2018
Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced that clinical data on AKCEA-APO(a)-LRx in patients with established cardiovascular disease (CVD) and elevated levels of lipoprotein(a), or Lp(a), will be presented at the American Heart Association Scientific Sessions in Chicago November 10-12, 2018.
-
Biopharma companies set to release financial reports next week have reported positive news in recent months.
-
Akcea Recognizes First Global Familial Chylomicronemia Syndrome (FCS) Awareness Day
11/2/2018
Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., today recognizes the inaugural Familial Chylomicronemia Syndrome (FCS) Awareness Day on November 2, 2018.
-
The U.S. Food and Drug Administration gave Akcea Therapeutics and its parent company Ionis Pharmaceuticals the green light for Tegsedi, its treatment for polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.
-
It looks to be a pretty busy week for the U.S. Food and Drug Administration (FDA), with a number of target action dates for various drugs. Some were delayed, and some were already approved, but there are still a number on the schedule. Here’s a look.
-
Akcea and Ionis Report Positive Data from Phase 2 Study of AKCEA-APO(a)-LRx
9/26/2018
Akcea Therapeutics, Inc. and Ionis Pharmaceuticals, Inc. announced positive topline results from a Phase 2 clinical study of AKCEA-APO(a)-LRx in patients with established cardiovascular disease (CVD) and elevated levels of lipoprotein(a), or Lp(a).
-
Akcea Therapeutics, based in Cambridge, Massachusetts, and Ionis Pharmaceuticals, headquartered in Carlsbad, California, released positive topline data from a Phase II trial of AKCEA-APO(a)-LRx in cardiovascular disease and lipoprotein(a).
-
A patient advocacy organization is putting its weight behind an effort to urge the U.S. Food and Drug Administration to reconsider its recent decision to reject a treatment for the rare lipid disorder familial chylomicronemia syndrome (FCS). That rejection lead to a round of layoffs at Akcea.
-
The biotech industry is fast-moving and dynamic, and staying on top of all the news can be hard for our busy readers. Here’s a look back at some of the top stories you may have missed this month.
-
A betting man may have placed a pretty strong wager on the U.S. Food and Drug Administration’s approval of Akcea Therapeutics’ Waylivra (volanesorsen), a treatment for the rare lipid disorder familial chylomicronemia syndrome (FCS).
-
This week has several action dates by the U.S. Food and Drug Administration (FDA) for a range of indications, including acne, intra-abdominal infections, and rare liver diseases. Here’s a look.
-
Beyond developing novel therapies for serious and rare diseases including FCS, Akcea is also dedicated to supporting the broader needs of the communities they serve.